Eidos Therapeutics (NASDAQ: EIDX) is one of 555 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Eidos Therapeutics to similar companies based on the strength of its risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares Eidos Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Eidos Therapeutics N/A -$33.29 million -14.78
Eidos Therapeutics Competitors $2.14 billion $224.95 million -3.96

Eidos Therapeutics’ peers have higher revenue and earnings than Eidos Therapeutics. Eidos Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Eidos Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eidos Therapeutics N/A -26.63% -25.58%
Eidos Therapeutics Competitors -1,563.74% -832.39% -27.72%

Institutional and Insider Ownership

30.9% of Eidos Therapeutics shares are held by institutional investors. Comparatively, 45.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Eidos Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eidos Therapeutics 0 1 6 0 2.86
Eidos Therapeutics Competitors 4757 13459 28236 1023 2.54

Eidos Therapeutics currently has a consensus target price of $30.29, suggesting a potential upside of 10.17%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.32%. Given Eidos Therapeutics’ peers higher possible upside, analysts plainly believe Eidos Therapeutics has less favorable growth aspects than its peers.


Eidos Therapeutics peers beat Eidos Therapeutics on 7 of the 12 factors compared.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.